The enrichment of the PI3K/AKT pathway in most differentially expressed genes (DEGs) suggests that the activation status of this pathway, which is commonly involved in tumor development, progression, and apoptosis, may be a key driver of chemoresistance in CC patients. This evidence concerns the gene AKT1 and neoplasm.